Unfettered basic research is often a privilege exclusive to periods of peace and stability. Pandemics, in contrast, necessitate a swift, directed response.

The sense of urgency that pandemics generate must nevertheless not be relegated to times of crisis. PROGENITER is a nationally recognized, multi-year research program that aims to discover, design, produce, characterize and deliver new treatments that target current and future infectious disease threats.

PROGENITER is a multidisplinary academic-industry partnership that will bolster Canada’s pandemic preparedness by creating a suite of ready-to-deploy antibody treatments for current health threats like COVID-19 and influenza, and position Canadian researchers and healthcare systems to respond rapidly to novel threats as they emerge.